

Minutes
Drug Utilization Review Board Meeting
DATE: 12/11/13



Meeting Purpose: Quarterly Open Board Meeting
Meeting opened at 6:00 PM by Chair, Adam Burrows

Agenda Items:

- I. Welcome and Introductory Remarks
- II. Acceptance of September 11, 2013 DUR Board Minutes
- III. Pharmaceutical Pipeline Preview
- IV. MassHealth Drug List Update
- V. DUR Operational Update
- VI. MassHealth Update Dr. Paul Jeffrey

Agenda Item	Discussion	Conclusions/Follow Up
Review of Minutes	The September 11, 2013 Minutes were reviewed and accepted as written	Follow Up: N/A
Action	September 11, 2013 Minutes approved as noted.	Conclusion: N/A

Agenda Item	Discussion	Conclusions/Follow Up
Pipeline Preview	A continuing education program, Pipeline Preview; A Summary of the Pharmaceutical Pipeline was presented including recent and anticipated FDA approvals, therapeutic class trends and anticipated generic availability.	Follow Up Informational
Action	<p>Most frequently studied therapeutic classes include:</p> <ul style="list-style-type: none"> • Oncology • Central Nervous System • Alimentary/Metabolic • Musculoskeletal • Cardiovascular • Immunological <p>Significant industry trends Include:</p> <ul style="list-style-type: none"> • Oncology – targeted and specialized therapies • Central Nervous System – multiple sclerosis therapies • Infectious Disease – development of improved hepatitis C treatments • Pain/Inflammation - abuse deterrent medications emerging 	Conclusions: N/A

	<ul style="list-style-type: none"> Cardiovascular – antidotes to oral anticoagulants, novel approaches to lipid lowering Rheumatic diseases – biologic agents, oral agents 	
--	--	--

Agenda Item	Discussion	Conclusions/Follow Up
MHDL Update	Overview of the drug list additions effective January 6, 2014 and the drug list changes effective January 21, 2014.	Follow Up: Informational
Action	<p>There are 22 new additions effective January 6, 2014. Changes in Prior Authorization status effective January 21, 2014 were also reviewed.</p> <p>Other updates included:</p> <ul style="list-style-type: none"> 1 new PA form 1 new initiative 	Conclusion: Changes in the MassHealth Drug List will continue to be provided as needed

Agenda Item	Discussion	Conclusions/Follow Up
DUR Operational Update	Quarterly Operations Update	Follow Up: Informational
Action	<p>DUR Operations monthly workload includes the following:</p> <ul style="list-style-type: none"> Average of 6,500 PA requests Average of 7,500 calls <ul style="list-style-type: none"> Average abandonment rate of 1.5 % Average treatment time of 4 minutes Average of 10 appeals Average of 500 Provider outreach calls Top 10 medications include: Suboxone, Lidoderm, Atorvastatin, Cymbalta, Abilify, Buprenorphine/naloxone, Lyrica, Montelukast, OxyContin and Crestor 	Conclusion: Quarterly operational updates will continue to be provided as needed.

Agenda Item	Discussion	Conclusions/Follow Up
MassHealth Update	Quarterly MassHealth Update	Follow Up Informational

Action	<p>Provided MassHealth Overview which includes the following:</p> <ul style="list-style-type: none"> • Revision to opiate management - letter will be mailed to providers • New copay structure coming 1/2014 • Online e-PA submission process in early 2014 	<p>Conclusion: Quarterly updates will continue to be provided as needed.</p>

Respectfully submitted by: Vincent Palumbo, Director of DUR

Date: _____